OTHER NEWS - Sept. 12, 1996
- Share via
Ciba-Geigy Executive Quits: The pharmaceutical company said James Callahan, the president of its U.S. pharmaceuticals division who was supposed to play a key role in its merger with Sandoz, resigned for “personal and professional” reasons. Ciba-Geigy and Sandoz are both based in Switzerland. Callahan had been designated as chief executive of the U.S. pharmaceuticals division of Novartis Pharmaceuticals, the company that will be created this year once Ciba has merged with Sandoz. The company is looking for a successor to Callahan. Bill Fullager, chief executive of Sandoz in the U.S., will become acting chief of Novartis Pharmaceuticals.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.